The t(14;18) translocation, which is characteristic of follicular lymphoma, results in the overexpression of the bcl-2 gene dependent upon regulatory elements within the bcl-2 5' flanking region and the immunoglobulin heavy chain gene enhancers. Con¯icting evidence exists on the eects of NF-kB expression on Bcl-2 levels in dierent cell types. Lymphoma cells with the t(14;18) translocation show high levels of nuclear NF-kB proteins. We observed decreased levels of endogenous Bcl-2 when the IkBa-super-repressor was expressed in a t(14;18) cell line. Deletion analysis of the bcl-2 promoter indicated that the repressive eect of the IkBa-super-repressor occurred through a region that contained no NF-kB consensus sequences. This highly active region contained a c-AMP response element (CRE) and several Sp1 binding sites. Chromatin immunoprecipitation assays with antibodies speci®c for the NF-kB and CREB/ATF family members, as well as Sp1, resulted in the isolation of this IkBa-super-repressor responsive region of the bcl-2 promoter. Mutation of the CRE and the two Sp1 sites in dierent combinations in bcl-2 reporter constructs resulted in the loss of bcl-2 promoter repression by the IkBa-super-repressor. We therefore conclude that the activation of bcl-2 by NF-kB in t(14;18) lymphoma cells is mediated through the CRE and Sp1 binding sites.
Introduction
The majority of follicular lymphomas are characterized by the translocation of the bcl-2 proto-oncogene from 18q21 to the immunoglobulin heavy chain (IgH) locus at 14q32 (Cleary et al., 1986; Tsujimoto and Croce, 1986; Tsujimoto et al., 1985) . This translocation results in the deregulated expression of the bcl-2 gene leading to elevated levels of bcl-2 mRNA and protein. As a key factor in cell survival, Bcl-2 functions to protect cells from apoptosis (Hockenberry et al., 1990; Vaux et al., 1988) . The elevated level of Bcl-2 in t(14;18) cells increases the survival of these cells and promotes the development of follicular lymphoma (Graninger et al., 1987) . Transgenic mice that constitutively overexpress Bcl-2 in their B cells display a polyclonal expansion of B cells with an increased survival rate but with no increase in cell cycling. In addition, progression to high-grade lymphoma is observed in these mice (McDonnell and Korsmeyer, 1991) . Although the mechanism of bcl-2 deregulation in t(14;18) cells remains unclear, elements within the IgH enhancers and the bcl-2 regulatory region are thought to play a role.
Two promoters mediate transcriptional control of the bcl-2 gene. The 5'-promoter (P1) is located 1386-1423 base pairs upstream of the translational start site (Seto et al., 1988) . This is a TATA-less, GC-rich promoter that displays numerous start sites. The start sites of the 3'-promoter (P2) are located 1.3 kilobases downstream of the P1 promoter. A major positive regulator of P1 activity is a c-AMP response element (CRE) (Wilson et al., 1996) . This element is not only essential for bcl-2 deregulation in t(14;18) cells, but it is also responsible for the positive regulation of bcl-2 expression during the activation of mature B cells and the rescue of immature B cells from calcium-dependent apoptosis (Ji et al., 1996; Wilson et al., 1996) . In addition, the CRE is essential for bcl-2 expression in neuronal cells (Riccio et al., 1999) and for estrogenreceptor activation of bcl-2 in mammary cells (Dong et al., 1999) . The P1 promoter also contains WT1 binding sites, which act as negative regulators of bcl-2 expression in t(14;18) and HeLa cells (Heckman et al., 1997; Hewitt et al., 1995) and as positive regulators in sporadic Wilm's tumors (Mayo et al., 1999) . The Myb transcription factors are important positive regulators of the bcl-2 P2 promoter (Frampton et al., 1996; Taylor et al., 1996) . In particular, A-Myb is a strong activator of P2 activity in t(14;18) cells and acts through the binding site for the homeodomain protein Cdx (Heckman et al., 2000) . Another positive regulator of the bcl-2 gene is the Ikaros family member Alios. This transcription factor becomes phosphorylated by Ras after IL-2 stimulation of T-cells and localizes to the nucleus where it binds to the P2 promoter (Romero et al., 1999) . Negative regulators of P2 activity include p53, which acts through the TATA element (Wu et al., 2001) , and the factors that interact with p binding sites, which are essential for bcl-2 down-regulation in immature B cells (Chen and Boxer, 1995) .
The NF-kB/Rel transcription factor family plays an important role in the regulation of apoptosis as well as other cellular processes (Sonenshein, 1997) . This family is composed of dierent subunits (p50/NF-kB1, p52/ NF-kB2, c-Rel, p65/RelA, and RelB) that form dimers and activate transcription through distinct binding sequences. Each subunit shares a conserved Rel homology domain important for DNA binding, dimerization and nuclear import (Baldwin, 1996) . The transcriptional activity of these factors is dependent on the subunits that comprise the dimers. In addition, the IkB family of inhibitory proteins in¯uences NF-kB/Rel activity. Binding of NF-kB/Rel proteins to IkB maintains the transcription factors in an inactive form in the cytoplasm by preventing translocation to the nucleus. The NF-kB/Rel proteins move to the nucleus following the degradation of the IkB proteins. This degradation is dependent on the phosphorylation and ubiquitination of the IkB proteins and can be induced by cytokines, mitogens or cell stress.
Several studies in dierent cell types have shown that treatment with known activators of NF-kB often results in an increase in pro-survival factors such as Bcl-2, Bcl-x L and B¯-1/A1 (Feng and Porter, 1999; Lee et al., 1999; Tamatani et al., 1999) . In addition, when the NF-kB inhibitor IkBa is expressed in either neuronal cells or EBV-transformed B lymphocytes, there is a corresponding decrease in Bcl-2 expression (Feng and Porter, 1999; Feuillard et al., 2000) . Chimeric mice repopulated with c-rel 7/7 rela 7/7 fetal liver hematopoietic cells lack mature B cells due to their impaired survival and reduced expression of Bcl-2 (Grossmann et al., 2000) . Although this study demonstrated the importance of the c-Rel and RelA subunits in the regulation of bcl-2 gene expression, it did not address whether the eect was direct or indirect. NFkB has been shown to bind to kB sequences in the promoters and directly activate expression of the bcl-x and b¯-1 genes, however, the mechanism of bcl-2 activation by NF-kB is unclear (Chen et al., 2000; Zong et al., 1999) . Treatment of some types of cells with NF-kB activators results in a delayed increase in bcl-2 expression, suggesting an indirect mechanism of activation. Furthermore, not all cells display bcl-2 upregulation when treated with NF-kB activators, indicating a cell-type dependent mechanism.
In this study, we examined the mechanism of bcl-2 regulation by NF-kB in t(14;18) lymphoma cells. We found that the t(14;18) lymphoma cell line DHL-4 displayed elevated levels of several NF-kB subunits and increased Bcl-2 expression. A decrease in endogenous Bcl-2 levels was observed in DHL-4 cells transfected with an IkBa super-repressor (IkBa-SR) expression vector. The repressive activity of the IkBa-SR was localized to a region in the bcl-2 promoter that lacked canonical kB binding sites. However, this highly active region contained several Sp1 binding sites and a CRE. By chromatin immunoprecipitation (ChIP) assay, we not only observed the in vivo interaction of the ATF/ CREB and Sp1 factors with this region but NF-kB proteins as well. In addition, mutation of the CRE and two Sp1 binding sites in dierent combinations abolished the ability of the IkBa-SR to repress a bcl-2 promoter construct. These results establish that NFkB proteins activate bcl-2 expression in t(14;18) cells through a novel mechanism involving interactions with other key transcription factors and their DNA binding elements.
Results

Constitutive activation of NF-kB in t(14;18) cells
Expression and activation of the dierent NF-kB/Rel subunits is dependent on cell type and stage of dierentiation as well as environmental factors. To determine if NF-kB played a role in bcl-2 up-regulation in t(14;18) cells, we examined the DHL-4 cell line for the expression of the dierent NF-kB subunits. As a comparison, we also examined NF-kB expression in a mature B cell line, DHL-9, that expresses lower levels of Bcl-2 and lacks a t(14;18), and an immature B cell line, Nalm-6. Using nuclear extracts from each of these cell lines, we found elevated levels of p50, RelA, c-Rel, and RelB in the DHL-4 cells as compared to DHL-9 or Nalm-6 cells ( Figure 1) . No dierence was observed in p52 levels. Similar results were observed in another t(14;18) cell line, DHL-6. To ensure equivalent protein loading, the amount of the Oct-1 transcription factor was also assessed.
TNFa further enhances bcl-2 expression in t(14;18) cells and protects the cells from apoptosis NF-kB can be activated by a number of cytokines including TNFa. To determine if TNFa aected bcl-2 expression in t(14;18) cells, we treated the DHL-4 cell Figure 1 NF-kB/Rel expression in human B cell lines. Nuclear extracts of the indicated cell lines were separated by SDSpolyacrylamide gel electrophoresis and transferred to nitocellulose. The blot was probed with antisera speci®c for p50, p52, RelA, c-Rel and RelB. Probing for Oct-1 was done to ensure equivalent protein loading Oncogene NF-kB activation of Bcl-2 CA Heckman et al line with varying amounts of TNFa and measured the amount of Bcl-2 and Bax proteins in the whole cell lysates of these cells. The amount of b-Actin was measured as a loading control. After 24 h of incubation, the amount of Bcl-2 protein increased by approximately twofold when DHL-4 cells were treated with 50 ng/ml TNFa (Figure 2) . No change was observed in Bax levels, demonstrating an increase in the ratio of the anti-apoptotic factor, Bcl-2, to the proapoptotic factor, Bax. In addition, when DHL-4 cells were treated with 50 ng/ml of TNFa for 24 h, we observed a slight decrease in apoptosis (data not shown).
Endogenous bcl-2 levels are decreased in cells that express the IkB-SR NF-kB dimers are prevented from translocating to the nucleus by their interaction with inhibitory proteins such as IkBa. A dominant-negative inhibitor of NFkB/Rel complexes was created from IkBa by mutation of two serine residues to alanines. The mutant protein, IkBa-SR, cannot be phosphorylated and subsequently degraded, so it retains the NF-kB/Rel complexes in the cytoplasm. As DHL-4 cells express high levels of NFkB and Bcl-2, we wished to determine if transfected IkBa-SR could repress endogenous Bcl-2 expression. Since the transfection eciency of DHL-4 cells is low, we also transfected the cells with the pHook2 vector and selected for transfected cells with hapten-coated magnetic beads. Whole cell extracts were prepared from the puri®ed cells and analysed by Western. When DHL-4 cells were transfected with the IkBa-SR expression vector, we detected a threefold decrease in endogenous Bcl-2 compared to the amount of Bcl-2 measured in cells transfected with an empty expression vector (Figure 3a) . A twofold increase in IkBa was observed in the IkBa-SR transfected cells. To assess the change at the transcriptional level, mRNA was collected from the transfected cells, and relative bcl-2 mRNA expression was quantitated by real-time PCR. With this assay, a decrease of approximately fourfold in bcl-2 transcripts in the IkBa-SR transfected cells as compared to the control cells was observed (Figure 3b ).
IkBa-SR represses the bcl-2 promoter
A schematic representation of the bcl-2 5'-flanking and untranslated region is shown in Figure 4a . Sequence analysis revealed at least one potential kB consensus sequence in the P1 promoter and two in the P2 promoter. By EMSA, binding of p50, RelA, and c-Rel was observed at the two P2 sites (data not shown). However, no change in promoter activity was observed when the two kB sites in the P2 promoter were either mutated or deleted in reporter constructs and then transfected into DHL-4 cells (data not shown). These results indicated that although NF-kB/Rel proteins interacted in vitro with sequences in the bcl-2 P2 promoter, these binding sites had no functional activity in DHL-4 cells. To further investigate whether NF-kB After incubation for 12 ± 14 h, sFV-expressing cells were selected using hapten-coated magnetic beads. Fifty mg of protein was separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. Bcl-2 and IkBa protein expression was assessed using antisera speci®c for each protein. A b-Actin antibody was used as a protein-loading control. (b) mRNA was harvested from the transfected cells, and the amount of bcl-2 mRNA was measured by a quantitative real-time RT ± PCR assay using a Bcl-2 speci®c¯uorogenic probe from Applied Biosystems. Bcl-2 mRNA levels were corrected by measuring GAPDH mRNA levels. The amount of Bcl-2 mRNA in the cells transfected with the empty expression vector was de®ned as 100, and the amount of bcl-2 mRNA from the IkBa-SR transfected cells was plotted relative to that value factors aect bcl-2 promoter activity, a reporter construct representing the full-length bcl-2 regulatory region (P1 and P2 promoters), as well as constructs representing the P1 promoter or the P2 promoter, were transfected into DHL-4 cells with the IkBa-SR expression vector or an empty expression vector. The IkBa-SR repressed the activity of the full-length bcl-2 promoter, and this repression was localized to the P1 promoter rather than to P2 (Figure 4b ).
Identification of the IkBa-SR responsive region of the bcl-2 promoter
To identify the region of the bcl-2 P1 promoter that was responsive to the IkBa-SR, several deletions of the P1 promoter were created and transfected with the IkBa-SR expression vector or an empty expression vector into DHL-4 cells (Figure 5a) . Surprisingly, most of the IkBa-SR repressive activity was localized between base pairs 71525 and 71640 in a region that lacked kB sequences, but which did contain a previously characterized CRE and several possible Sp1 binding sites ( Figure 5b ). A small amount of repression was also observed with the minimal P1 promoter construct ( Figure 5b ). The sequence represented in this construct (71286 to 71341) contained a potential kB or Sp1 binding site.
Characterization of the proteins interacting with the IkBa-SR responsive region at 71525 to 71640 by in vitro assays
A number of studies have reported on the importance of the CRE for bcl-2 promoter activity in B lymphocytes and neuronal cells (Ji et al., 1996; Riccio et al., 1999; Wilson et al., 1996) . Another study has also noted the relevance of the CRE and two Sp1 sites for the up-regulation of bcl-2 by estradial in a breast cancer cell line (Dong et al., 1999) . To determine if the NF-kB/Rel complexes interacted with the CRE or the previously described Sp1 sites, EMSA was performed using labeled oligonucleotides representing each element. Our laboratory has previously described the interaction of ATF-2 and CREB-1 with the CRE (Ji et al., 1996; Wilson et al., 1996) . Several speci®c complexes were formed when DHL-4 nuclear extract was incubated with a labeled probe representing the CRE ( Figure 6a , lane 1). Formation of these complexes was inhibited by competition with a 100-fold molar excess of cold wild-type probe, but competition with a sequence containing a mutation in the CRE, a sequence representing the kB binding site from the HIV LTR, or a nonspeci®c sequence had no eect on speci®c complex formation ( Figure 6b , lanes 2 ± 5, respectively). Formation of complexes B and C was (7) or the IkBa-SR expression vector (+). The luciferase activity of the promoters in the presence of the empty expression vector was assigned a value of 100, and the activity of the promoters in the presence of the IkBa-SR expression vector was plotted relative to that value promoter deletion constructs and an empty expression vector (7) or the IkBa-SR expression vector (+). The activity of the full-length bcl-2 P1 promoter construct with the empty expression vector was assigned a value of 100, and the activity from the other transfections was plotted relative to that value inhibited by the addition of an antibody speci®c for ATF-1 and CREB-1 (Figure 6a , lane 6). In a previous study, we observed that the slowest migrating complex A could be super-shifted with an antibody speci®c for ATF-2 (Wilson et al., 1996) . Incubation with antibodies speci®c for p50, p52, RelA, and c-Rel had no eect on complex formation (Figure 6a , lanes 7 ± 10), however, incubation with an anti-RelB antibody inhibited the formation of the previously uncharacterized complex D (Figure 6a, lane 11) . Complex formation was not altered by incubation with an anti-Sp1 antibody or with an antibody speci®c for a non-transcription factor protein (Figure 6a , lanes 12 and 13).
To investigate the possibility that the Sp1 sites upstream of the CRE were involved in NF-kB activation of bcl-2 as well, EMSA was performed with an oligonucleotide representing each site. Speci®c complex formation was not observed at the site located at 71590 (data not shown), however, speci®c complexes were formed when a labeled probe representing the Sp1 site at 71578 was incubated with DHL-4 nuclear extract ( Figure 6b , lane 1). Formation of these complexes was inhibited with the addition of a 100-fold molar excess of unlabeled sequence ( Figure 6b , lane 2), but no inhibition was observed with the addition of a 100-fold molar excess of sequence containing a three-base pair mutation to the Sp1 site or a nonspeci®c sequence (Figure 6b , lanes 3 and 4). Although in vitro translated Sp1 has been reported to bind to this site (Dong et al., 1999) , we did not observe a change in complex formation with the addition of an antibody speci®c for Sp1 (Figure 6b , lane 5). Furthermore, no alteration in the complexes was observed with the addition of antibodies speci®c for p50, p52, RelA, c-Rel, RelB, ATF-1/CREB-1 or a nonspeci®c protein (Figure 6b , lanes 6 ± 12). However, when the mutant sequence was labeled and incubated with DHL-4 nuclear extract, there was a signi®cant reduction in complex formation, indicating the importance of this site for protein binding (Figure 6b, lane 13) .
Since we did not clearly detect Sp1 binding at the 71578 site by EMSA, we further characterized the protein complexes binding to this site by UV crosslinking followed by denaturing polyacrylamide gel electrophoresis (Figure 6c) . UV cross-linking of both the upper and lower EMSA complexes (labeled in Figure 6b ) yielded a major protein product of 31 kDa after correction for the bound probe (Figure 6c , lanes 1 and 2). In addition, faintly labeled proteins of approximately 81, 50 and 22 kDa were derived from the upper EMSA complex (Figure 6c , lane 1). The 81 and 22 kDa products were also observed with the lower EMSA complex (Figure 6c, lane 2) .
Identification of the proteins that interact in vitro with the IkBa-responsive region in the minimal promoter
The IkBa-SR expression vector was also able to repress the minimal bcl-2 P1 promoter region. This sequence contained a potential kB sequence that overlapped with a potential Sp1 binding site. EMSA of this region with DHL-4 nuclear extract revealed complexes that could be inhibited by the addition of a 100-fold molar excess of the unlabeled sequence (Figure 6d, lanes 1 and 2) . However, the addition of a 100-fold molar excess of a sequence containing a four base change to the kB/Sp1 site or a 100-fold molar excess of nonspeci®c sequence did not inhibit the formation of the complexes (Figure 6d, lanes 3  and 4) . Addition of antibodies speci®c for p50, RelA or c-Rel did not result in a change in complex formation, but a super-shift was observed when an anti-Sp1 antibody was added (Figure 6d, lanes 5 ± 8) . No change in complex formation was observed with the addition of an antibody speci®c for a nontranscription factor protein (Figure 6d, lane 9) .
Identification of the proteins interacting in vivo with the IkBa-SR responsive regions in the bcl-2 P1 promoter
Since the in vitro protein-DNA binding studies provided evidence for the interaction of RelB with the IkB-responsive regions of the bcl-2 promoter, but not the other NF-kB family members, we wished to determine if additional NF-kB/Rel interactions could be observed in vivo with this region. For this purpose, we used the chromatin immunoprecipitation (ChIP) assay as described by Boyd and Farnham (1999) . In this assay, DHL-4 cells were treated with formaldehyde to cross link proteins to DNA. The cross-linked chromatin was then extracted and sheared to an average length of 500 bp. Immunoprecipitations were performed using the sheared chromatin and antibodies speci®c for the dierent NF-kB/Rel subunits, the ATF/CREB family members, Sp1, or a control antibody speci®c for IgG. Following immunoprecipitation, the puri®ed DNA was subjected to PCR analysis using two sets of primers speci®c for each of the IkBa-SR responsive regions in the bcl-2 P1 promoter. The ®rst set produced a 193-bp amplicon of the sequence 71443 to 71636. This included the CRE and putative Sp1 site at 71537 and 71578, respectively. Antibodies speci®c for ATF-1, ATF-2, CREB-1 or CBP resulted in the precipitation of this IkBa-SR responsive region, but this region was not selected when using the antibody to IgG or no antibody at all (Figure 7a) . Moreover, enrichment of this same region was also observed when antibodies speci®c for p50, p52, RelA, c-Rel, RelB and Sp1 were used for immunoprecipitation ( Figure  7b ). These ChIP results provided evidence that the NF-kB and Sp1 factors, as well as the ATF and CREB proteins, interact with this IkBa-SR responsive region in vivo.
To identify the proteins interacting in vivo with the Sp1 binding site at 71332, a second set of primers was designed to produce a 233-bp amplicon from 71278 to 71511. This sequence was enriched when using antibodies speci®c for Sp1, p52, and RelA ( Figure 7b ). Some selection was also observed with antibodies speci®c for p50 and c-Rel, but not when anti-RelB or anti-IgG antibodies were used for immunoprecipitation (Figure 7b ). These results showed that Sp1 as well as p52, RelA, and possibly p50 and c-Rel, interact with this sequence in vivo. (a) EMSA of the bcl-2 CRE with DHL-4 nuclear extract. Lane 1 contains no competitor; lane 2, 100-fold molar excess of cold bcl-2 CRE oligonucleotide; lane 3, 100-fold molar excess of cold mutant CRE oligonucleotide; lane 4, 100-fold molar excess of an oligonucleotide representing the kB sequence from the HIV LTR; lane 5, 100-fold molar excess of nonspeci®c oligonucleotide; lane 6, an antibody that recognizes all CREB/ATF family members; lane 7 ± 13, antibodies speci®c for p50, p52, RelA, c-Rel, RelB, Sp1, or a non-transcription factor protein, respectively. The speci®c complexes A ± D are indicated by arrows. (b) Lanes 1 ± 12, EMSA of the 5' Sp1 site using DHL-4 nuclear extract. Lane 1 contains no competitor; lane 2, 100-fold molar excess of cold 5' Sp1 oligonucleotide; lane 3, 100-fold molar excess of cold mutant 5' Sp1 oligonucleotide; lane 4, 100-fold molar excess of nonspeci®c oligonucleotide; lanes 5 ± 12, antibodies speci®c for Sp1, p50, p52, RelA, c-Rel, RelB, all CREB/ATF family members, or a nonspeci®c protein, respectively. Lane 13, EMSA of the labeled mutant 5' Sp1 sequence. Arrows indicate the speci®c upper and lower complexes. (c) Denaturing SDS-polyacrylamide gel electrophoresis of the UV cross-linked complexes formed with the 5' Sp1 site and DHL-4 nuclear extract. Protein from the upper complex is shown in lane 1, and lane 2 represents protein from the lower complex in Figure 6B . The migration of the molecular mass markers is indicted on the left. (d) EMSA of the 3' Sp1 site with DHL-4 nuclear extract. Lane 1 contains no competitor; lane 2, 100-fold molar excess of cold 3' Sp1 oligonucleotide; lane 3, 100-fold molar excess of cold mutant 3' Sp1 oligonucleotide; lane 4, 100-fold molar excess of HIV LTR kB sequence; lane 5, 100-fold molar excess of nonspeci®c oligonucleotide; lanes 6 ± 10, antibodies speci®c for p50, RelA, c-Rel, Sp1, or a non-speci®c protein, respectively
The CRE and Sp1 binding sites mediate the repressive activity of the IkBa-SR on the bcl-2 P1 promoter in t(14;18) cells To assess the relevance of the CRE and Sp1 binding sites for the IkBa-SR repression of the bcl-2 P1 promoter, reporter constructs containing mutations in these sites were generated ( Figure 8a ). As shown in Figure 8b , the IkBa-SR expression vector repressed P1 promoter activity if the reporter construct contained mutations in either Sp1 site, but the repression was reduced with mutation of the CRE. When the 5' Sp1 site at 71578 was mutated along with the CRE at 71537, the repressive activity of the IkBa-SR was lost entirely. Mutation of the 3' Sp1 site at 71332 had only a small eect on bcl-2 P1 activity and when that site was mutated with the 5' Sp1 site at 71578 or the CRE, very little repression by the IkBa-SR was observed (Figure 8b ). When all three sites were mutated in one construct, only a low level of promoter activity was detected (Figure 8b ). Together, these results indicate that the majority of the repression by IkBa is mediated by the CRE at 71537 with some cooperative interaction with the 5' Sp1 site at 71578. To a lesser extent, the 3' Sp1 site at 71332 also plays a role.
Discussion
NF-kB/Rel activity is regulated both at the level of gene expression and at a post-translational level by interactions with inhibitory proteins. A number of studies have suggested a possible role for the NF-kB/ Rel factors in bcl-2 up-regulation in dierent cell types, yet the mechanism of bcl-2 activation by NF-kB was unclear. One of the activators of NF-kB, TNFa, has been shown to increase Bcl-2 expression in primary neurons but not in Tax-transfected cells (Tamatani et al., 1999; Tsukahara et al., 1999) . The increase in Bcl-2 expression induced by TNFa in the primary neurons could be inhibited by the expression of the mutant protein IkBa-SR (Tamatani et al., 1999) . We found an increase in Bcl-2 expression when t(14;18) cells were treated with 50 ng/ml TNFa. Although the change in the level of Bcl-2 expression was small, this was most Figure 7 NF-kB/Rel family members interact in vivo with the bcl-2 P1 promoter. (a) ChIP analysis of the bcl-2 CRE and 5' Sp1 site. Chromatin proteins and DNA were cross-linked by formaldehyde treatment in DHL-4 cells, the cross-linked chromatin was collected and sheared, and then fractionated using speci®c antibodies as indicated. The positive control is represented by the total input fraction. Negative controls included a no chromatin sample, no antibody sample, and nonspeci®c IgG. Precipitated DNA was analysed by PCR using primers that ampli®ed a 193-bp product that included the region with the 5' Sp1 site and CRE. The PCR products were visualized by ethidium bromide staining of a 2% agarose gel. (b) ChIP analysis of the bcl-2 3' Sp1 site. Cross-linked chromatin was fractionated using the indicated speci®c antibodies. The PCR primers ampli®ed a 233-bp sequence that included the 3' Sp1 site likely due to the pre-existing high levels of activated NF-kB in these cells. Further correlation between NFkB activity and Bcl-2 expression in t(14;18) lymphomas was demonstrated when we transfected an IkBa-SR expression vector into DHL-4 cells. We observed a decrease in endogenous Bcl-2 mRNA and protein levels, which is consistent with studies performed in primary neurons, neuroblastoma or lymphoblastoid cells (Feng and Porter, 1999; Feuillard et al., 2000; Tamatani et al., 1999) . However, not all cell types have shown a correlation between NF-kB/Rel activity and Bcl-2 expression. Although Feuillard et al. observed a decrease in Bcl-2 expression with IkBa-SR induction in transformed lymphoblastoid cells, Cahir-McFarland et al. saw a decrease in B¯-1/A1 expression, but not in Bcl-2 or Bcl-x L expression (Cahir-McFarland et al., 2000; Feuillard et al., 2000) . In addition, induced expression of c-Rel or RelA in a ®brosarcoma cell line resulted in increased expression of Bcl-x L but not Bcl-2 (Chen et al., 2000) .
Regulation of gene expression by NF-kB/Rel complexes typically occurs through a 10 bp binding sequence. Our results showed that the IkBa-SR could repress the bcl-2 P1 promoter, and this repression was limited to a highly active region that contained a CRE and several possible Sp1 binding sites. Mutation of the CRE and a nearby Sp1 site dramatically reduced bcl-2 promoter activity and interfered with the repression by the IkBa-SR. We have noted the cooperation of the CRE and the sequence containing the Sp1 site (previously called the upstream regulatory element) in the regulation of the bcl-2 promoter in prior studies (Wilson et al., 1996) . The additional mutation of a second Sp1 site in the P1 minimal promoter region abolished bcl-2 promoter activity completely. By ChIP assay, we demonstrated the in vivo interaction of ATF-1, ATF-2, CREB-1, CBP, and Sp1 with the region containing the CRE and upstream Sp1 site. But more interestingly, we also observed in vivo binding by p50, p52, RelA, c-Rel and RelB to this region. ChIP analysis of the downstream Sp1 site resulted in its isolation by antibodies speci®c for Sp1, p52, RelA, and to a lesser extent p50 and c-Rel. The in vivo interaction of NF-kB/Rel factors with this region indicated that this Sp1 site might also be important for the activation of bcl-2 by NF-kB. Although a single, large complex of transcription factors may be formed at the sites in the bcl-2 promoter, a more plausible explanation is that a number of complexes form at these sequences and contain dierent combinations of the factors. We were not able to isolate the regions that included the kB sequences in the P2 promoter by ChIP assay (data not shown), which further indicated that NF-kB does not activate bcl-2 through these sites in t(14;18) cells. Our results suggest a complex mechanism of bcl-2 activation by NF-kB that includes interactions with other transcription factors and their DNA binding sites.
A number of reports have demonstrated cooperation between ATF/CREB and NF-kB/Rel factors in transcriptional activation (Butscher et al., 1998; Du et al., 1993; Whitley et al., 1994) . The cooperation required adjacent CRE and kB seqeunces, but a direct interaction between the factors was also demonstrated (Kaszubska et al., 1993) . In addition, Sp1 and NF-kB were shown to cooperate in the activation of HIV-1 gene expression (Perkins et al., 1993) . This cooperation was dependent on adjacent Sp1 and kB sequences in the HIV LTR and required the direct interaction of Sp1 and RelA through their DNA binding domains (Perkins et al., 1994) . The v-rel gene product was found to up-regulate a promoter containing Sp1 binding sites in the absence of kB consensus sequences (Sif et al., 1993) . However, in vitro binding by v-Rel to that promoter was not observed. Our results indicate that NF-kB/Rel factors activate the bcl-2 promoter through interactions with the ATF/CREB and Sp1 factors and their binding sites rather than directly through a kB consensus sequence. This is in contrast to a recent study by Kurland and colleagues, which suggested that p50 homodimers activate bcl-2 expression by directly binding to kB sequences (Kurland et al., 2001) . Moreover, one of the kB sequences that is inactive in t(14;18) cells was found to mediate positive regulation of bcl-2 P2 promoter activity in prostate carcinoma cells (Catz and Johnson, 2001 ). Although we found the sites identi®ed by Kurland as well as Catz to be inactive in t(14;18) cells, there could be cell-speci®c usage of the kB sequences in the bcl-2 promoter. Interestingly, Akt/protein kinase B and protein kinase C (PKC), known activators of NF-kB, have also been shown to activate bcl-2 expression through the CRE (Pugazhenthi et al., 2000; Wilson et al., 1996) . While the activation of bcl-2 could be mediated by the ability of Akt or PKC to phosphorylate CREB, another possibility is that Akt and PKC also activate bcl-2 through NF-kB.
By in vitro binding assays, the only NF-kB/Rel family member we could detect interacting with the IkBa-SR responsive region was RelB. We were not able to detect Sp1 binding to the site upstream of the CRE in vitro, although a previous study has shown that in vitro translated Sp1 interacts with this site (Dong et al., 1999) . By UV cross-linking assay, we observed a number of proteins directly interacting with this potential Sp1 site in vitro. The strongest complex was formed with a protein of 31 kDa, which is smaller than Sp1 or any of the NF-kB/Rel subunits. However, we did observe fainter signals representing proteins of 81 kDa and 50 kDa, which approximate the sizes of cRel, p50, and p52. One possibility is that Sp1 interacts indirectly with this sequence and forms a complex with the other proteins bound to this site. Further studies will need to be done to identify the 31 kDa protein involved at this site and to investigate if this protein is required for activation of bcl-2 expression by NF-kB. We may not be able to observe complete complex formation in vitro at the CRE and Sp1 sites since many proteins interact with these sites, and the complexes may not be stable during EMSA. This could explain the discrepancy between our results from the in vivo and in vitro binding studies.
Our studies indicate that NF-kB regulates bcl-2 expression, and recent studies have shown that Bcl-2 can regulate NF-kB activity. The primary mechanism of this activation is through the regulation of IkBa by Bcl-2. Over-expression of Bcl-2 in myocytes, breast cancer cells, and photoreceptor cells results in lower levels of IkBa and increased NF-kB activity (Crawford et al., 2001; de Moissac et al., 1998 de Moissac et al., , 1999 Ricca et al., 2000) . Although the mechanism of IkBa repression by Bcl-2 is not clear, studies indicate that this repression requires the Bcl-2 BH4 domain and is related to the phosphorylation and degradation of IkBa (de Moissac et al., 1999; Ricca et al., 2000) . These studies, together with our results, suggest a potential feedback pathway where NF-kB increases Bcl-2 expression, which in turn inhibits IkBa, further enhancing NF-kB activity.
Dysregulated NF-kB/Rel gene expression and activity have been observed in a number of disorders including many cancers (Luque and Gelinas, 1997). Hodgkin's lymphomas display constitutive NF-kB/Rel activity while c-Rel is ampli®ed in some diuse large cell lymphomas (Go et al., 2000; Rao et al., 1998; Rayet and Gelinas, 1999) , and Rel family members are expressed at high constitutive levels in many lymphomas and chronic lymphocytic leukemias (Munzert et al., 2000) . The increased NF-kB/Rel activity in these malignancies may lead to increased Bcl-2 expression by mechanisms that are similar to those we have de®ned in t(14;18) lymphoma cells. Since the IkBa-SR that we utilized preferentially inhibits NF-kB complexes that contain either c-Rel or RelA, it is likely that inhibition of the additional Rel family members that we observed binding to the bcl-2 promoter in vivo would decrease Bcl-2 levels even further. Decreased levels of Bcl-2 have been shown to increase the sensitivity of cells to the induction of apoptosis by chemotherapeutic agents (Klasa et al., 2000; Konopleva et al., 2000; Pepper et al., 2001; Wacheck et al., 2001) . This raises the possibility that NF-kB inhibitors could be useful in the treatment of follicular lymphomas and of other lymphomas that show increased expression of Bcl-2.
Materials and methods
Plasmid constructs
The bcl-2 promoter-luciferase reporter constructs have been described previously (Heckman et al., 1997; Wilson et al., 1996) . Polymerase chain reaction (PCR) subfragment cloning or insertion of restriction sites using site-directed mutagenesis methods followed by subfragment cloning was performed to create deletions of the bcl-2 P1 promoter. Constructs with mutations to the CRE or Sp1 binding sites were derived from the 71640 construct using a site-directed mutagenesis method. The oligonucleotide sequences used as mutagenic primers are as follows with the transcription factor binding site underlined and the mutated bases in boldface: CRE MUT: GAATGAACCGTGGGCCTTTACGCACAGG; 5'-Sp1 MUT: GTGGCTCAGAGGTCCGCTCTTTCTTTC; 3' Sp1 MUT: CGGGGCTCCGGGCCGAGGCTGCCGGCG-GCCGTC.
All plasmid sequences were con®rmed by sequencing. The expression vector encoding the IkBa-SR cDNA was under the control of a cytomegalovirus (CMV) immediate-early promoter. The empty control vector also contained a CMV promoter. The pHook2 vector was obtained from Invitrogen.
Cell lines
DHL-4, Nalm-6, and DHL-9 are human B cell lines that have been described previously (Chen and Boxer, 1995; Ji et al., 1996; Wilson et al., 1996) . All cells were maintained in RMPI medium with 10% fetal calf serum, L-glutamine, penicillin and streptomycin.
Western blot analysis
Crude nuclear extracts were prepared from DHL-4, Nalm-6, and DHL-9 cells and 50 mg of protein was diluted with 26Laemmli buer and loaded onto a 10% SDS-polyacrylamide gel, electrophoresed and transferred onto nitrocellulose as previously described (Heckman et al., 2000) . Detection of p50/NF-kB1, p52/NF-kB2, RelA, c-Rel, RelB and Oct-1 was performed with antibodies from Santa Cruz Biotechnology. Chemiluminescence was performed using the Western blotting luminol reagent (Santa Cruz Biotechnology).
TNFa treatment
For each treatment, 2610 7 cells at mid-log phase were pelleted and resuspended in 5 ml supplemented RPMI medium. Human recombinant TNFa (Sigma) was added to cells at ®nal concentrations of 0, 5, 10, 20 or 50 ng/ml. Following 24 h incubation at 378C, the cells were lysed and subjected to Western blot analysis as described above. The Bcl-2 and Bax antibodies were obtained from Santa Cruz Biotechnology while the b-Actin antibody was obtained from Sigma.
Selection of transfected cells
DHL-4 cells were transfected with 10 mg pHook2 vector and 10 mg of IkBa-SR vector or 10 mg of empty expression vector. The transfected cells were allowed to recover for 12 ± 14 h at 378C, pelleted, resuspended in 1 ml supplemented RPMI medium, then incubated for 30 min with hapten-coated magnetic beads (Invitrogen) to select for sFV expression. Selected cells were washed three times with supplemented RPMI medium, and then subjected to either a protein or mRNA isolation procedure.
Protein isolation and immunoblotting
Selected cells were washed with ice-cold PBS and then lysed. The protein concentration of the lysates was determined, and 50 mg of each sample was diluted with 26Laemmli buer and loaded onto a 10% SDS ± PAGE gel. Following electrophoreses and transfer onto nitrocellulose, immunoblotting was done with Bcl-2 and IkBa antibodies (Santa Cruz Biotechnology). Detection of b-Actin was performed to ensure equivalent protein loading.
mRNA isolation and real-time quantitative RT ± PCR
Selected cells were pelleted and mRNA was extracted using the Oligotex Direct mRNA Miniprep kit (Qiagen). Bcl-2 mRNA levels were quantitated on the ABI Prism 7900-HT Sequence Detection System using the One Step RT ± PCR Master Mix and Human Bcl-2 Pre-Developed TaqMan Assay Reagent (Applied Biosystems). Bcl-2 expression was corrected by the assessment of GAPDH mRNA levels using the TaqMan GAPDH Control Reagents (Applied Biosystems).
Transient transfections and luciferase assays
For each transfection, 2610 7 cells at mid-log phase were pelleted and washed twice with unsupplemented RPMI medium. The cells were resuspended in 0.75 ml of RPMI and mixed with 20 mg DEAE-Dextran. The cells were then placed in a 0.4 cm electroporation cuvette with 10 mg reporter DNA and 0.1 mg pRL-TK (Promega). Electroporation was carried out at 960 mF and 320 V using a Bio-Rad Gene Pulser. Following electroporation, the cells were placed in culture with 25 ml supplemented RPMI medium and allowed to incubate for 48 h. For cotransfections, 10 mg of the reporter plasmid was transfected with 5 mg of the IkBa-SR expression vector or empty expression vector and 0.1 mg pRL-TK. Reporter gene activity was assessed using the DualLuciferase Assay system (Promega). Results were normalized to Renilla luciferase activity.
EMSA
The double-stranded oligonucleotides used for EMSA of the CRE and two Sp1 binding sites are shown below with the transcription factor binding site underlined and the mutated bases in boldface. Also included is the double-stranded oligonucleotide representing the NF-kB binding site from the HIV-LTR. The oligonucleotides were synthesized with 5'-overhangs and labeled by a ®ll-in reaction with [a-32P]dCTP and Klenow polymerase. For the CRE, the binding conditions were described previously (Ji et al., 1996) . For the Sp1 sites, the binding reaction mixture contained 10 mM Tris-HCl (pH 7.5), 30 mM NaCl, 0.5 mM EDTA, 1 mM dithiothreitol, 5% glycerol, 1 mg poly-(dI-dC), 0.5 ng (10 4 cpm) of endlabeled DNA oligonucleotide probe, and 20 mg of protein from crude nuclear extract. The mixture was incubated at room temperature for 20 min. For DNA competition experiments, a 100-fold molar excess of unlabeled oligonucleotide was added prior to incubation. For the super-shift experiments, 4 mg of antibody was added to the completed binding reaction and this was incubated for 1 h at 48C. All antibodies were obtained from Santa Cruz Biotechnology.
Electrophoresis was performed in a 0.56Tris borate-EDTA 5% polyacrylamide gel at 20 mA and 48C.
UV cross-linking and SDS-polyacrylamide gel electrophoresis EMSA was performed as described above with the 5' Sp1 site oligonucleotide except that the binding reaction was scaled up by ®vefold. UV cross-linking and SDS-polyacrylamide electrophoresis were performed as described previously (Phan et al., 1996) .
Chromatin immunoprecipitation assay
The ChIP assay was performed as outlined by Boyd and Farnham (1999) . For each immunoprecipitation reaction, 2610 7 DHL-4 cells at mid-log phase were used. Formaldehyde was added directly to the cells to a ®nal concentration of 1%, and cross-linking was allowed to proceed for 10 min at room temperature. The cross-linking reaction was stopped by the addition of glycine to a ®nal concentration of 0.125 M and incubation at room temperature for 5 min. The cells were pelleted, washed three times with ice-cold PBS, and then lysed. Nuclei were collected and lysed. Chromatin was sheared to an average length of 500 ± 600 bp sonication (206, 10 s pulses). The resultant suspension was precleared with Staphylococus A (Staph A) cells and divided equally for each immunoprecipitation assay. For each assay, 4 mg of antibody was added to the chromatin suspension, and this mixture was incubated at 48C overnight with slow rotation. All antibodies were obtained from Santa Cruz Biotechnology. For negative controls, assays were set up that contained no chromatin, no antibody or anti-rabbit IgG (Santa Cruz Biotechnology). For those precipitations with monoclonal antibodies, 1 mg of secondary antibody was added, and the incubation was continued for an additional hour. The immune complexes were precipitated with blocked Staph A cells, washed several times, and then eluted. The supernatant from the no antibody control was saved for use as the total input control. All samples were subjected to RNase A digestion, cross-link reversal, proteinase K digestion, and phenol-chloroform extraction. The remaining DNA was ethanol precipitated and resuspended in 30 ml Tris-EDTA (TE). DNA from the total input control was diluted to 0.5 mg/ml with TE. Precipitation of bcl-2 promoter regions was assessed by PCR ampli®cation using 2 ml of each sample. The following oligonucleotide sequences were used as primers: 5' Sp1+CRE coding: GCCTTTAACCCGGGCCAGGGAG; 5' Sp1+CRE noncoding: GAGGGGCGGGCGCGGGAGGAA; 3' Sp1 coding: CAGAGAATGAAGTAAGAGGACAGGCAC; 3' Sp1 noncoding: GCCTCCCGGAGCCCCGCCGCGCA.
PCR products were resolved on 2% agarose gels and visualized by ethidium bromide staining.
